First authors of the article -Jeff Weitz/Hamilton Health Sciences; Robert Harrington/Weill Cornell Medicine
May 2, 2026, 13:10
Targeting FXIa As a Safer Anticoagulant Target Than FXa in LIBREXIA Trial – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by et al, adding:
”Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
This narrative review details the pharmacological rationale for targeting FXIa as a safer anticoagulant target than FXa, and outlines how phase 2 findings informed milvexian dosing regimens across three phase 3 LIBREXIA trials enrolling approximately 50,000 patients with AF, ACS, or ischemic stroke.”
Title: Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
Authors: Jeff Weitz, Robert Harrington on behalf of the LIBREXIA Program Executive Council
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda